Education And Debate The marketing of a disease: female sexual dysfunction BMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7484.192 (Published 20 January 2005) Cite this as: BMJ 2005;330:192 Article Related content Metrics Responses Peer review Related articles Feature Evening the score on sex drugs: feminist movement or marketing masquerade? Published: 17 October 2014; BMJ 349 doi:10.1136/bmj.g6246 Views & Reviews Spam medicine Published: 14 July 2008; BMJ 337 doi:10.1136/bmj.a810 See more Indonesian doctors risk losing licence if they castrate paedophiles BMJ October 25, 2016, 355 i5762; DOI: https://doi.org/10.1136/bmj.i5762 Anabolic steroid use BMJ October 13, 2016, 355 i5023; DOI: https://doi.org/10.1136/bmj.i5023 Testosterone supplementation for “low T” is not supported by evidence, review concludes BMJ September 22, 2016, 354 i5166; DOI: https://doi.org/10.1136/bmj.i5166 Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink BMJ September 22, 2016, 354 i4823; DOI: https://doi.org/10.1136/bmj.i4823 Approved drugs are to be studied for use in Alzheimer’s disease BMJ September 19, 2016, 354 i5063; DOI: https://doi.org/10.1136/bmj.i5063 Cited by... Hypoactive sexual desire disorder: inventing a disease to sell low libidoAbstract Fulltext PDF Evening the score on sex drugs: feminist movement or marketing masquerade?Abstract Fulltext PDF Developing diseases for drugs to treat?Abstract Fulltext PDF Merging of marketing and medical science: female sexual dysfunctionAbstract Fulltext PDF Testosterone patches for female sexual dysfunctionAbstract Fulltext PDF Benefits and harms of direct to consumer advertising: a systematic reviewAbstract Fulltext PDF